» Articles » PMID: 11799170

Persistence and Fitness of Multidrug-resistant Human Immunodeficiency Virus Type 1 Acquired in Primary Infection

Overview
Journal J Virol
Date 2002 Jan 19
PMID 11799170
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

This study examines the persistence and fitness of multidrug-resistant (MDR) viruses acquired during primary human immunodeficiency virus infection (PHI). In four individuals, MDR infections persisted over the entire study period, ranging from 36 weeks to 5 years, in the absence of antiretroviral therapy. In stark contrast, identified source partners in two cases showed expected outgrowth of wild-type (WT) virus within 12 weeks of treatment interruption. In the first PHI case, triple-class MDR resulted in low plasma viremia (1.6 to 3 log copies/ml) over time compared with mean values obtained for an untreated PHI group harboring WT infections (4.1 to 4.3 log copies/ml). Increasing viremia in PHI patient 1 at week 52 was associated with the de novo emergence of a protease inhibitor-resistant variant through a recombination event involving the original MDR virus. MDR infections in two other untreated PHI patients yielded viremia levels typical of the untreated WT group. A fourth patient's MDR infection yielded low viremia (<50 to 500 copies/ml) for 5 years despite his having phenotypic resistance to all antiretroviral drugs in his treatment regimen. In two of these PHI cases, a rebound to higher levels of plasma viremia only occurred when the M184V mutation in reverse transcriptase could no longer be detected and, in a third case, nondetection of M184V was associated with an inability to isolate virus. To further evaluate the fitness of MDR variants acquired in PHI, MDR and corresponding WT viruses were isolated from index and source partners, respectively. Although MDR viral infectivity (50% tissue culture infective dose) was comparable to that observed for WT viruses, MDR infections in each case demonstrated 2-fold and 13- to 23-fold reductions in p24 antigen and reverse transcriptase enzymatic activity, respectively. In dual-infection competition assays, MDR viruses consistently demonstrated a marked replicative disadvantage compared with WT virus. These results indicate that MDR viruses that are generated following PHI can establish persistent infections as dominant quasispecies despite their impaired replicative competence.

Citing Articles

Predominance of positive epistasis among drug resistance-associated mutations in HIV-1 protease.

Zhang T, Dai L, Barton J, Du Y, Tan Y, Pang W PLoS Genet. 2020; 16(10):e1009009.

PMID: 33085662 PMC: 7605711. DOI: 10.1371/journal.pgen.1009009.


Amino-acid inserts of HIV-1 capsid (CA) induce CA degradation and abrogate viral infectivity: Insights for the dynamics and mechanisms of HIV-1 CA decomposition.

Amano M, Bulut H, Tamiya S, Nakamura T, Koh Y, Mitsuya H Sci Rep. 2019; 9(1):9806.

PMID: 31285456 PMC: 6614453. DOI: 10.1038/s41598-019-46082-2.


Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study.

Lee D, Lee J Osteoporos Int. 2018; 30(3):659-666.

PMID: 30535785 DOI: 10.1007/s00198-018-4778-0.


Neutral Theory and Rapidly Evolving Viral Pathogens.

Frost S, Magalis B, Kosakovsky Pond S Mol Biol Evol. 2018; 35(6):1348-1354.

PMID: 29688481 PMC: 6279309. DOI: 10.1093/molbev/msy088.


Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohort.

Stekler J, Milne R, Payant R, Beck I, Herbeck J, Maust B PLoS Med. 2018; 15(3):e1002537.

PMID: 29584723 PMC: 5870941. DOI: 10.1371/journal.pmed.1002537.


References
1.
Batisse D, Karmochkine M, Mohamed A, Piketty C, Kazatchkine M, Belec L . Persistence of HIV-1 variants harbouring the zidovudine resistance mutation at pol codon 215 in patients who respond to triple combination therapy. AIDS. 1998; 12(7):824-5. View

2.
Little S, Daar E, DAquila R, KEISER P, Connick E, Whitcomb J . Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA. 1999; 282(12):1142-9. DOI: 10.1001/jama.282.12.1142. View

3.
Hirsch M, Conway B, DAquila R, Johnson V, Brun-Vezinet F, Clotet B . Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. JAMA. 1998; 279(24):1984-91. DOI: 10.1001/jama.279.24.1984. View

4.
Hecht F, Grant R, Petropoulos C, Dillon B, Chesney M, Tian H . Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med. 1998; 339(5):307-11. DOI: 10.1056/NEJM199807303390504. View

5.
Miller M, Anton K, Mulato A, Lamy P, Cherrington J . Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. J Infect Dis. 1998; 179(1):92-100. DOI: 10.1086/314560. View